期刊文献+

系统性红斑狼疮继发肺动脉高压临床对比分析 被引量:1

原文传递
导出
摘要 目的对比分析并探讨系统性红斑狼疮(SLE)继发肺动脉高压症(PAH)患者的临床特征。方法在我科住院的93例SLE患者按入选标准筛查出PAH组24例和非PAH组69例,对比分析两组患者的临床特征和检测结果数据。结果临床特征方面,两组患者雷诺现象、运动后呼吸困难、肺间质病变和多浆膜腔积液比较差异有统计学意义(P〈0.05);与非PAH组比较,PAH组实验室检测血小板减少、高滴度抗RNP抗体、球蛋白升高、C3减少、类风湿因子升高和循环免疫复合物增多,差异有统计学意义(P〈0.05),其中循环免疫复合物增多明显(P〈0.01)。结论SLE继发PAH患者总体预后不良,早期诊断及早期药物干预有望逆转或者延缓病情的进展。彩色多普勒超声心动图是进行PAH的筛查和疗效监测的有效手段。雷诺氏症、肺间质病变、高滴度抗RNP抗体等均是PAH发病的相关因素和危险因子。轻中度患者的PAH与SLE活动性相关。
出处 《中国实用医刊》 2013年第5期69-71,共3页 Chinese Journal of Practical Medicine
  • 相关文献

参考文献10

  • 1Simonneau G,Galie N,Rubin LJ. Clinical classification of pulmonary hypertension[J].J Coll Cardiol,2004,(Suppl):5-12.
  • 2Galie N,Manes A,Farahani KV. Pulmonary arterial hypertension associated to connective tissue diseases[J].Lupus,2005,(09):713-717.doi:10.1191/0961203305lu2206oa.
  • 3Johnson SR,Granton JT. Pulmonary hypertension in systemic sclerosis and systemic lupus erythematosus[J].European Respiratory Review,2011,(122):277-286.
  • 4Arnaud L,Agard C,Haroche J. Pulmonary arterial hypertension in systemic lupus erythematosus[J].Revue De Medecine Interne,2011,(11):689-697.
  • 5Bijl M,Bootsma H,Kallenberg CG. Pulmonary arterial hypertension in systemic lupus erythematosus:should we bother[J].Rheumatology(Oxford),2009,(12):1471-1472.
  • 6李海云,郑毅.结缔组织病合并间质性肺疾病的研究进展[J].中华风湿病学杂志,2005,9(7):438-441. 被引量:28
  • 7Hassoun PM. Pulmonary arterial hypertension? complicating connective tissue diseases[J].Seminars in Respiratory and Critical Care Medicine,2009,(04):429-439.doi:10.1055/s-0029-1233312.
  • 8Condliffe R,Kiely DG,Peacock A J. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era[J].Journal of Respiratory and Critical Care Medicine,2009,(02):151-157.
  • 9Kato M,Kataoka H,Odani T. The short-term role of corticosteroid therapy for pulmonary arterial hypertension associated with connective tissue diseases:report of five cases and a literature review[J].Lupus,2011,(10):1047-1056.
  • 10Prabu A,Patel K,Yee CS. Prevalence and risk factors for pulmonary arterial hypertension in patients with lupus[J].Rheumatology(Oxford),2009,(12):1506-1511.

二级参考文献16

  • 1Veeraraghavan S, Nicholson AG, Wells AU, et al. Lung fibrosis:new classifications and therapy. Curr Opin Rheumatol, 2001, 13:500-504.
  • 2Vassallo R, Thomas CF. Advances in treatment of rheumatic interstitial lung disease. Curr Opin Rheumatol, 2004, 16: 186-191.
  • 3Latsi PI, Wells AU. Evaluation and management of alveolitis and interstitial lung disease in scleroderma. Curr Opin Rheumatol,2003, 15: 748-755.
  • 4MacDonald SLS, Rubens MB, Hansell DM, et al. Nonspecific interstitial pnermonia and usual interstitial pneumonia:comparative appearances and diagnostic accuracy of high-resolution computed tomography. Radiology, 2001, 221: 600-605.
  • 5Cheema GS, Quismorio FP Jr. Interstitial lung disease in systemic sclerosis. Curr Opin Pulm Med, 2001, 7: 283-290.
  • 6Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum, 1994, 37: 1283-1289.
  • 7Witt C, Borges AC, John M, et al. Pulmonary involvement in diffuse cutaneous systemic sclerosis: bronchoalveolar fluid granulocytosis predicts progression of fibrosing alveolitis. Ann Rheum Dis, 1999, 58: 635-640.
  • 8Selman M, Thannichal V J, Pardo A, et al. Idiopathic pulmonary fibrosis. Drugs, 2004, 64: 405-430.
  • 9Palas I, Ioannidis JA, Malagari K, ct al. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.J Rheumatol, 2002, 29: 298-304.
  • 10Griffiths B, Miles S, Moss H, et al. Systemic sclerosis and interstitial lung disease:a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function. JRheumatol, 2002, 29: 2371-2378.

共引文献27

同被引文献9

  • 1Ruiz-Irastorza G,Garmendia M ,Villar I,et ahPulmonary hyper- tension in systemic lupus erythematosus: prevalence, predic- tors and diagnostic strategy.Autoimmun Rev,2013,12(3):410.
  • 2Nobre C,Mesquita D,Thomas B,et al.Echocardiography in pulmonary hypertension.Chest, 2013,144 (4) : 1426.
  • 3Gali N,Palazzini M,Manes A.Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed.Eur Respir J,2010,36(5) :986.
  • 4Lau E M,Manes A,Celermajer D S,et al.Early detection of pulmonary vascular disease in pulmonary arterial hyperten- sion: time to move forward.Eur Heart J,2011,32(20) :2489.
  • 5Cefle A,Inanc M,Sayarlioglu M,et al.Pulmonary hypertension in systemic lupus erythematosus: relationship with antiphos- pholipid antibodies and severe disease outcome.Rheumatol Int,2011,31 (2) :83.
  • 6Lau E M,Manes A,Celermajer D 5,et al.Early detection o1 pulmonary vascular disease in pulmonary arterial hyperten- sion: time to move forward.Eur Heart J,2011,32(20) :2489.
  • 7Shah D,Kiran R,Wanehu A,et al.Oxidative stress in sys- temic lupus erythematosus: relationship to Thl cytokine and disease activity. Immunol Lett ,2010,129( 1 ) :7.
  • 8Lin JL,Thomas PS.Current perspectives of oxidative stress and its measurement in chronic obstructive pulmonary dis- ease.COPD ,2010,7 (4) :291.
  • 9滕佳临,张巍.系统性红斑狼疮合并肺动脉高压患者临床特点分析[J].中华医学杂志,2014,94(13):969-972. 被引量:14

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部